Prihlásiť sa Zaregistrujte sa zadarmo

Zisková marža spoločnosti Adma Biologics Inc

Aká je hodnota metriky Zisková marža spoločnosti Adma Biologics Inc?

Hodnota metriky Zisková marža spoločnosti Adma Biologics Inc je -10.94%

Aká je definícia metriky Zisková marža?



Zisková marža (Profit margin) je percento čistého zisku z celkových tržieb.

Profit margin is calculated with the selling price (or revenue) taken as base times 100. It is the percentage of selling price that is turned into profit. Profit percentages are calculated to find the ratio of profit to cost of an investment. Profit margin is an indicator of a company's pricing strategies and how well it controls costs. Differences in competitive strategy and product mix cause the profit margin to vary among different companies. The profit margin is used mostly for internal comparisons. It is difficult to accurately compare the net profit ratio for different entities. Individual businesses' operating and financing arrangements vary so much that different entities are bound to have different levels of expenditure, so that comparison of one with another can have little meaning. A low profit margin indicates a low margin of safety: higher risk that a decline in sales will erase profits and result in a net loss, or a negative margin.

Zisková marža spoločností v sektore Health Care sektor na NASDAQ v porovnaní so spoločnosťou Adma Biologics Inc

Čomu sa venuje spoločnosť Adma Biologics Inc?

adma is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of primary immune deficiency disease (pidd) and certain infectious diseases. adma's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. the target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. adma’s lead product candidate, ri-002, has completed a phase iii clinical trial in patients with pidd and has met the primary endpoint. a bla for ri-002 was accepted by the fda on september 18, 2015. the company has received u.s. patent 9,107,906. for more information, please visit the company's website at www.admabiologics.com.

Firmy s metrikou zisková marža podobnou spoločnosti Adma Biologics Inc



  • Hodnota metriky Zisková marža spoločnosti IGG je -10.97%
  • Hodnota metriky Zisková marža spoločnosti IGG Inc je -10.97%
  • Hodnota metriky Zisková marža spoločnosti Jaywing plc je -10.96%
  • Hodnota metriky Zisková marža spoločnosti Greenhill & Co Inc je -10.95%
  • Hodnota metriky Zisková marža spoločnosti HangKan je -10.94%
  • Hodnota metriky Zisková marža spoločnosti Rohit Ferro-Tech je -10.94%
  • Hodnota metriky Zisková marža spoločnosti Adma Biologics Inc je -10.94%
  • Hodnota metriky Zisková marža spoločnosti Spirit Airlines je -10.93%
  • Hodnota metriky Zisková marža spoločnosti NEXTDC je -10.92%
  • Hodnota metriky Zisková marža spoločnosti Smartsheet Inc je -10.92%
  • Hodnota metriky Zisková marža spoločnosti ETS je -10.90%
  • Hodnota metriky Zisková marža spoločnosti Science in Sport plc je -10.90%
  • Hodnota metriky Zisková marža spoločnosti ST International je -10.90%